The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage ...

The Chile-based Laboratory is using SOPHiA GENETICS' platform to advance its research capabilities with blood disorders BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood can ...

University of Saskatchewan's (USask) Advanced Diagnostics Research Laboratory will use SOPHiA DDM™ Platform to advance research on ovarian cancer care BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to s ...

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results recently published in npj Preci ...

BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT. The fireside chat will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be a ...

BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief Operating Officer, Ross Muken, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 2:35 p.m. EDT. The fireside chat will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be a ...

Financial Data and Key Metrics Changes - Total revenue for the full year 2023 was $62.4 million, representing a year-over-year growth of 31% compared to $47.6 million in 2022 [52] - Gross profit for the full year 2023 was $42.9 million, up from $31.3 million in 2022, indicating a 37% increase [10] - Adjusted gross profit for the full year 2023 was $45 million, a 39% increase from $32.4 million in 2022 [10] - Operating loss for the full year 2023 was $74.8 million, improved from $87.8 million in 2022 [54] - Net dollar retention for the year improved to 130%, up from 102% in 2022 [53] Business Line Data and Key Metrics Changes - Solid tumor revenue grew above the company average in 2023, with HRD applications seeing over 150% revenue growth [25] - The company added 35 new core genomic customers in Q4 2023, contributing to a total of 450 core genomic customers by year-end [24][28] - Clinical revenue fell in line with internal plans, with a small amount of biopharma-related revenue shifting to the first half of 2024 [9] Market Data and Key Metrics Changes - U.S. revenue grew 70% to $9.5 million in 2023, up from $5.6 million in 2022 [40] - Usage of the platform in India grew 70% from 2022 to 2023 [43] - The company saw strong growth in the Asia Pacific region, delivering over 50% growth [78] Company Strategy and Development Direction - The company aims to capitalize on the launch of new liquid biopsy offerings, including MSK-ACCESS powered with SOPHiA DDM, with a sales pipeline approaching double-digit millions [31] - Plans for 2024 include launching new capabilities in hem-onc and rare diseases, as well as a full modernization of SOPHiA DDM [32] - The company is focused on expanding its multimodal capabilities and partnerships with biopharma customers [15][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in the next two-plus years, citing strong organic growth and net dollar retention [45][90] - The company anticipates a moderate negative impact on reported results in 2024 due to exchange rate volatility and the cessation of COVID-related contributions [55] - Management highlighted the importance of balancing investment for future growth while maintaining revenue momentum [115] Other Important Information - Total cash burn for the fourth quarter of 2023 was $9.5 million, down from $10.6 million in the prior year [77] - The company has invested over $400 million in AI capabilities since inception, with a team of over 200 data scientists and engineers [7] Q&A Session Summary Question: Can you contextualize the liquid biopsy business and the new platform adoption? - Management noted that the liquid biopsy business is still small relative to the overall platform, but there is significant momentum and interest in new platform adoption [63][65] Question: What is the outlook for biopharma contributions and the path to profitability? - Management indicated that biopharma revenue is still in nascent stages but showed strong performance, with a focus on expanding partnerships to drive growth [66][90] Question: How sustainable is the growth in HRD applications? - Management expressed confidence in the sustainability of HRD growth, particularly as the class of PARP inhibitors expands beyond ovarian cancer [102] Question: What are the expectations for new sequencing technology impacts? - Management acknowledged the potential for longer onboarding times due to new sequencer diversity but emphasized that this could expand the overall market [99][106]

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue grew 27% year-over-year to $17.0 million; Constant currency revenue excluding COVID-related revenue also grew 27% year-over-yearGross margins were 70% on a reported basis and 73% on an adjusted basis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2023) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2023 SOPHiA GENETICS SA Rolle Report of the statutory auditor to the General Meeting on the consolidated financial statements 2023 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Rolle Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of SOPHiA GENETICS SA and its subsidiaries (the Group), which comprise the consolidated ...